Literature DB >> 10403005

Immunophenotyping of acute lymphoblastic leukemia in pediatric patients by three-color flow cytometric analysis.

P Tiensiwakul1, T Lertlum, I Nuchprayoon, P Seksarn.   

Abstract

Immunophenotyping of acute lymphoblastic leukemia (ALL) in children using three-color flow cytometry was carried out at Chulalongkorn Hospital, Bangkok, Thailand. Of 38 patients with acute lymphoblastic leukemia, 65.8% were identified as common ALL, 15.8% were B-ALL, and 18.4% were T-ALL. Of these 38 cases, there were 4 cases of infantile leukemia. Relapsed cases of leukemia were found most in B-ALL up to 3 out of 6 cases and to a lesser extent in T-ALL (1 of 7 cases) and c-ALL (1 of 25 cases). Our data showed the CD markers expression for common ALL (c-ALL) were CD19+/10+ (100%), CD20+ (24%), CD22+ (100%), HLA-DR+ (70.1%), and CD34+ (58.8%). CD markers expression for B-ALL were CD19+ (100%), CD20+ (33.3%), CD22+ (80%), and HLA-DR+ (80%). CD markers expression for T-ALL were CD3+ (42.9%), CD5+ (100%), CD7+ (85.7%). Myeloid aberrant expressions were found in c-ALL (25-37.5%), B-ALL (20%), and T-ALL (14.3%). The significance of the aberration is discussed. The immunophenotyping classification of ALL as c-ALL, B-ALL, and T-ALL is useful in prognosis and treatment.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10403005

Source DB:  PubMed          Journal:  Asian Pac J Allergy Immunol        ISSN: 0125-877X            Impact factor:   2.310


  2 in total

1.  Chronic lymphoproliferative disorders at an Indian tertiary cancer centre - the panel sufficiency in the diagnosis of chronic lymphocytic leukaemia.

Authors:  Geeta V Patil Okaly; Ashwini R Nargund; Venkataswamy E; Prashanth K Jayanna; Chandra Rao Juvva; Shilpa Prabhudesai
Journal:  J Clin Diagn Res       Date:  2013-07-01

2.  T-cell Acute Lymphoblastic Leukemia with del (7) (q11.2q22) and Aberrant Expression of Myeloid Markers.

Authors:  Ahmad Ahmadzadeh; Sajedeh Saedi; Kaveh Jaseb; Ali Amin Asnafi; Arash Alghasi; Najmaldin Saki
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2013
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.